Disease modification in systemic sclerosis: Do integrated approaches offer new challenges?

Zeitschrift fur Rheumatologie

Volumn 72, Issue 4, 2013, Pages 326-328

  Cutolo, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ARTICLE; CAPILLAROSCOPY; CLINICAL TRIAL (TOPIC); ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; MESENCHYMAL STEM CELL; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; SYSTEMIC SCLEROSIS; TISSUE OXYGENATION;

DELIVERY OF HEALTH CARE, INTEGRATED; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84877782496     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-013-1157-2     Document Type: Article

References (33)

1. Derk CT (2011) Disease-modifying drugs for systemic sclerosis: why have we not found them yet? Expert Rev Clin Immunol 7:399-401
2. Mendoza FA, Keyes-Elstein LL, Jimenez SA (2012) Systemic sclerosis disease modification clinical trials design: quo vadis? Arthritis Care Res (Hoboken) 64:945-954
3. Geyer M, Müller-Ladner U (2011) The pathogenesis of systemic sclerosis revisited. Clin Rev Allergy Immunol 40:92-103
4. Hirschl M, Hirschl K, Lenz M et al (2006) Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 54:1974-1981
5. Cutolo M, Pizzorni C, Sulli A (2007) Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy. Arthritis Rheum 56:2102-2103
6. Herrick AL, Cutolo M (2010) Clinical implications from capillaroscopic analysis in patients with Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 62:2595-2604
7. Jimenez SA, Derk CT (2004) Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 140:37-50
8. Dulmovits BM, Herman IM (2012) Microvascular remodeling and wound healing: a role for pericytes. Int J Biochem Cell Biol 44:1800-1812
9. Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42-54
10. Distler JH, Jüngel A, Pileckyte M et al (2007) Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum 561:4203-4215
11. Müller-Ladner U, Distler O, Ibba-Manneschi L et al (2009) Mechanisms of vascular damage in systemic sclerosis. Autoimmunity 42:587-595
12. Manetti M, Guiducci S, Matucci-Cerinic M (2011) The origin of the myofibroblast in fibroproliferative vasculopathy: does the endothelial cell steer the pathophysiology of systemic sclerosis? Arthritis Rheum 63:2164-2167
13. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:199-210
14. Bhattacharyya S, Wei J, Varga J (2011) Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 8:42-54
15. Widyantoro B, Emoto N, Nakayama K et al (2010) Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 121:2407-2418
16. Nataraj D, Ernst A, Kalluri R (2010) Idiopathic pulmonary fibrosis is associated with endothelial to mesenchymal transition. Am J Respir Cell Mol Biol 43:129-130
17. Mouthon L, Mehrenberger M, Teixeira L et al (2011) Endothelin-1 expression in scleroderma renal crisis. Hum Pathol 42:95-102
18. Soldano S, Montagna P, Brizzolara R et al (2012) Transforming growth factor-β and endothelin-1 induce endothelial-to-mesenchymal transition in cultured human endothelial cells. Arthritis Rheum 64:abstract 1493
19. Li Z, Jimenez SA (2011) Protein kinase Cdelta and c-Abl kinase are required for transforming growth factor beta induction of endothelial-to- mesenchymal transition in vitro. Arthritis Rheum 63:2473-2483
20. Cutolo M, Sulli A, Secchi ME, Pizzorni C (2006) Capillaroscopy and rheumatic diseases: state of the art. Z Rheumatol 65:290-296
21. Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? A pilot study. Ann Rheum Dis 71:1636-1639
22. Cutolo M, Sulli A, Pizzorni C, Accardo S (2000) Nailfold videocapillaroscopy assessment of microvascular damage in systemic sclerosis. J Rheumatol 27:155-160
23. Avouac J, Fransen J, Walker UA et al (2011) EUSTAR Group. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 70:476-481
24. LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28:1573-1576
25. Johnson SR, Fransen J, Khanna D et al (2012) Validation of potential classification criteria for systemic sclerosis. Arthritis Care Res (Hoboken) 64:358-367
26. Smith V, Decuman S, Sulli A et al (2012) Do worsening scleroderma capillaroscopic patterns predict future severe organ involvement? a pilot study. Ann Rheum Dis 71:1636-1639
27. Smith V, De Keyser F, Pizzorni C et al (2011) Nailfold capillaroscopy for day-to-day clinical use: construction of a simple scoring modality as a clinical prognostic index for digital trophic lesions. Ann Rheum Dis 70:180-183
28. Sulli A, Pizzorni C, Smith V et al (2012) Timing of transition between capillaroscopic patterns in systemic sclerosis. Arthritis Rheum 64:821-825
29. Tugwell P, Pincus T, Yocum D et al (1995) Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 333:137-141
30. Kuhn A, Haust M, Ruland V et al (2010) Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 49(7):1336-1345
31. Piera-Velazquez S, Jimenez SA (2012) Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases. Fibrogenesis Tissue Repair 5(Suppl 1):S7
32. Guiducci S, Bellando Randone S, Bruni C et al (2012) Bosentan fosters microvascular de-remodelling in systemic sclerosis. Clin Rheumatol 31:1723-1725
33. Cutolo M, Zampogna G, Vremis L et al (2013) Longterm effects of endothelin receptor antagonism on microvascular damage evaluated by nailfold capillaroscopic analysis in systemic sclerosis. J Rheumatol 40:40-45